European Commission opens antitrust probe into Sanofi over flu vaccine marketing

The European Commission launched an antitrust investigation on Friday into French pharmaceutical giant Sanofi over alleged anticompetitive practices in the marketing of its flu vaccine Efluelda, designed for people over 60. The probe, opened by the EU’s competition watchdog, focuses on whether Sanofi misled healthcare professionals and policymakers to stifle competition in the market for enhanced influenza vaccines.

The investigation centers on Sanofi’s promotion of Efluelda, a high-dose flu vaccine marketed specifically for vulnerable populations aged 60 and older. According to multiple reports published today, EU regulators are examining claims that Sanofi may have engaged in practices that distort competition, including potentially misleading campaigns aimed at undermining rival vaccines. The European Commission confirmed the probe in Brussels, while German and French media outlets reported the development shortly afterward.

Sanofi’s Efluelda has been positioned as providing greater protection against seasonal influenza for older adults, a demographic particularly vulnerable to severe complications from the virus. The vaccine’s enhanced formulation has been a key differentiator in a competitive market where several manufacturers vie for contracts with national health systems across Europe. The EU’s move suggests regulators suspect Sanofi may have used its market position to suppress competition rather than through legitimate product differentiation.

The investigation was announced the same day by the Financial Times , Handelsblatt , ORF , Le Monde , and The European Sting , all citing EU sources. The probe follows growing scrutiny of pharmaceutical marketing practices in Europe, particularly in sectors where public health procurement plays a central role.

A Sanofi spokesperson declined immediate comment, while the European Commission stated that the investigation is at an early stage and no conclusions have been reached. If found to have breached EU competition rules, Sanofi could face significant fines and be required to adjust its marketing practices. The case also raises broader questions about transparency in vaccine promotion, especially for products intended for high-risk groups during flu season.

The investigation comes amid heightened awareness of influenza prevention in Europe, where aging populations and seasonal outbreaks place increasing pressure on public health systems. Regulators are likely to examine not only Sanofi’s promotional activities but also the broader dynamics of vaccine procurement and pricing in the sector.